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Abstract
Background: Despite the declining incidence of gastric cancer, mortality rate remains high due to late presentation.
We aimed to evaluate the sensitivity of miRNA as a diagnostic marker for gastric cancer in the circulation.
Methods: Plasma samples from 3 independent groups comprise 123 gastric cancer patients and 111 healthy controls
for miRNA profiling from microarray screening.
Results: Microarray data showed that 25 miRNAs were upregulated in gastric cancer patients and 6 highly expressed
miRNAs (miR-18a, miR-140-5p, miR-199a-3p, miR-627, miR-629 and miR-652) were selected for validation. In an
independent validation set, levels of miR-627, miR-629 and miR-652 were significantly higher in gastric cancer patients
than healthy controls (P <0.0001). An algorithm with improved sensitivity and specificity as gastric cancer classifier was
adopted and validated in another random set of 15 plasma samples. Results showed that combination of 3 miRNAs
obtained the highest area under curve, with a cut-off at 0.373, with a sensitivity of 86.7 % and a specificity of 85.5 %.
Conclusion: This study revealed a three-miRNA signature as a promising classifier for gastric cancer, and greatly
enhances the feasibility of circulating miRNAs as non-invasive diagnostic marker for this disease.
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Background
Gastric cancer is one of the leading causes of cancer
mortality in the world, and it has a particularly high inci-
dence in Asian countries including China. Despite the
declining incidence of gastric cancer, there are still more
than 1 million cases newly diagnosed and 850,000 deaths
globally each year [1]. The mortality rate remains high
due to late presentation, since early stage of gastric
cancer is either asymptomatic or presents with non-
specific symptoms. For advanced diseases, the overall
5-year survival following surgical resection is 30–40 %, as
compared to 70–90 % in early stage [2]. To date, endo-
scopic and pathological examinations are the common
techniques for cancer diagnosis. Despite their sensitivity
and specificity to visualize and locate the site of malig-
nancy, these approaches are invasive in nature which
impede patients from routine screening for gastric cancer.
Conventional serum tumour markers, namely, carcinoem-
bryonic antigen (CEA) and carbohydrate antigen 19.9,
however, are not tissue specific and expressed in most of
the gastrointestinal cancers. Our group has shown that
serum migration-inhibitory factor (MIF) had a better
diagnostic value than CEA, however, combined serum
MIF and CEA would have a better 5-year survival progno-
sis than individual marker [3]. Serum E-cadherin level was
found to be positively correlated with disease recurrence,
and this could be a better marker than CEA in predicting
disease recurrence [4, 5]. Therefore, there is an urge to
look for a non-invasive diagnostic biomarker that could be
easily detected in serum, plasma or urine for early diagno-
sis for gastric cancer to greatly improve the mortality rate.
Many recent studies revealed that microRNAs (miRNAs)
were actively involved in development, differentiation,
inflammation, and pathogenesis of various malignancies.
They belong to a class of small non-coding RNAs about
19–25 nucleotides in length, and are able to bind
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complementary sequences in 3′-untranslated regions
(3′-UTR) of various target mRNAs to promote deg-
radation or translational repression [6]. Studies have
shown that over 30 % of human genes are regulated
by miRNAs, in which a single miRNA controls over
hundreds of RNA [7, 8]. MiRNAs also function as
tumour suppressors or oncogenes in various types of
cancer. Because miRNAs are very specific for different
types of tissues and even for types of cells within
those tissues, they are potentially useful for diagnosis,
predicting clinical outcome or therapeutic targets in
cancer patients. By comparing the miRNA expression
profiles in tumour versus adjacent non-tumour
tissues, distinct patterns of up- or down-regulation of
miRNAs could be found in different types of cancers
[9–12]. These cancer specific miRNAs expression
patterns could be used for diagnosis or monitor the
efficiency of follow-up treatment.
With the development of microarray platforms,
researchers could easily differentiate the oncogenic or
tumour suppressive miRNAs in various human malig-
nancies. We have previously developed a robust
protocol to profile miRNA expression in the circula-
tion of colorectal cancer patients [12]. With the use
of PCR-based miRNA array, we could profile the
miRNA expression in plasma, as well as in paired
tumour and adjacent non-tumour tissues. There are
studies reporting that miRNA is more stable than
mRNA in the circulation and yet specific miRNA is
originate from tumour site [13, 14]. In this study, we
compare the miRNA expression profile in plasma of
gastric cancer patients with healthy controls. We
further validated the levels of miRNAs in three inde-
pendent sets of gastric cancer patients and associated
with tumour progression. We proposed that circulat-
ing miRNA signature could act as a potential molecu-
lar marker for diagnosis and therapeutic targets for
gastric cancer.
Results
Discovery of miRNA expression profile in the plasma of
gastric cancer patients
It is speculated that miRNAs originate from gastric
tumor will enter into the circulation, and could be
potentially used as molecular marker for early detec-
tion of gastric cancer. An overview of the study
design is illustrated in Fig. 1. To identify the miRNA
expression profiles in gastric cancer, we first com-
pared the miRNA expression in plasma of gastric
cancer patients (n = 5) with healthy controls (n = 5)
using microarray analysis. There were 77 (out of 377)
miRNAs differentially expressed in gastric cancer, of
which 25 were upregulated (Table 1) and 52 were
downregulated (Additional file 1: Table S1), with a
cut-off value of 2-fold difference.
Selection of potential miRNAs as diagnostic markers
We then carried out real-time qPCR to validate these
25 upregulated miRs in both plasma and paired
tumor/non-tumor tissues samples from the same
patients (n = 20) (data not shown). Next, we selected
top 6 most upregulated miRs (miR-18a, miR-140-5p,
199a-3p, miR-627, miR-629 and mir-652) that signifi-
cantly expressed in both plasma and tissues samples
for the second part of the study. We then selected
these 6 upregulated miRNAs for further validation
using real-time qPCR analysis in an initial training
set (TS) containing 50 gastric cancer cases of different
stages (stages I, n = 8; stage II, n = 11; stage III, n = 15;
stage IV, n = 16) and 50 age- and sex-matched healthy
controls. The expression levels of miR-18a, miR-140-5p,
199a-3p, miR-627, miR-629 and miR-652 were com-
parable with the microarray data (Fig. 2a-f ). Results
showed that the fold change of these miRNAs initially
screened by microarray were consistent with the
qPCR analysis. The AUC of miR-627 (AUC = 0.7968),
Fig. 1 An overview of the workflow of the study design
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miR-629 (AUC = 0.8545) and miR-652 (AUC = 0.7512)
were highest in this training set.
Validation of miR-627, miR-629 and miR-652 as biomarkers
to differentiate gastric cancer cases
We next evaluated the expression levels of miR-18a,
miR-140-5p, 199a-3p, miR-627, miR-629 and miR-652 in
an independent validation set (VS) consist of 58 gastric
cancer cases of different stages (stages I, n = 8; stage II,
n = 2; stage III, n = 26; stage IV, n = 22) and 46 age- and
sex-matched healthy controls. Results showed that
gastric cancer patients have a higher expression levels
of miR-627, miR-629 and miR-652 relative to healthy
controls (Fig. 3a-f ), all of which were statistically
significant (P < 0.0001).
Since miR-627, miR-629 and miR-652 had the highest
AUC in both TS and VS, we further examined the ex-
pression levels in 36 paired primary cancer tissues from
VS, by comparing the tumor tissues with its adjacent
non-tumor counterparts. In consistent with the plasma
data, tumor tissue levels of miR-627, miR-629 and
miR-652 were significantly higher than in non-tumor
counterparts (P < 0.05, <0.01 and <0.01 respectively).
The ROC curves analysis of these miRNAs showed
that the AUC were 0.6698, 0.6782 and 0.6921 accord-
ingly (Fig. 4a-c).
Optimization of miRNAs as potential gastric cancer classifiers
To improve the specificity of the classifier to differentiate
gastric cancer cases with non-gastric cancer cases, we
designed a new algorithm by combining miRNAs into
classifier A (miR-627 and miR-629), classifier B (miR-627
and miR-652), classifier C (miR-629 and miR-652) and
classifier D (miR-627, miR-629 and miR-652). To test
whether these four classifiers could be more specific to de-
tect gastric cancer cases, we tested these four classifiers in
the TS and VS respectively. By applying classifier D to TS,
it could use to distinguish gastric cancer cases from
healthy controls and the AUC increased to 0.902 (Table 2).
The sensitivity was 0.855 and the specificity was 0.757.
And we observed a high significant different between gas-
tric cancer cases and healthy controls (P < 0.0001, t-test).
Similarly, the same classifier apply to VS, the AUC was
determined to be 0.969. The probability scores were mark-
edly different between gastric cancer cases and healthy
controls (P < 0.001, t-test). We observed a sensitivity of
0.920 and specificity was 0.935. We observed that all these
classifiers have improved sensitivity and specificity than
individual miRNA, in which classifier D obtained the
highest AUC among all the classifiers.
In this setting, we further examined the efficacy based
on classifier D in the random set (RS) containing 15
gastric cancer cases of different stages (stages I, n = 4;
stage II, n = 2; stage III, n = 5; stage IV, n = 4) and
healthy controls. Gastric cancer cases were signifi-
cantly differentiated with healthy controls by more
than 10-folds, the AUC was determined to be 0.941
(P < 0.0001; Fig. 5a). In addition, if we combined the
datasets of TS and VS, the optimal cut-off value of
classifier D was at 0.373 with a sensitivity of 86.7 %
and a specificity of 85.5 %, and the AUC was 0.941
(Fig. 5b).
Association with progression of gastric cancer
To examine whether the gastric cancer classifier is corre-
lated with pathological stage, we analyze the relative ex-
pression of classifier D with the TNM stage in combined
datasets of TS and VS. Data showed that there is no direct
correlation between the expression of classifier D and the
TNM stage (Fig. 6), this implicate miRNA expression is a
stage-independent diagnostic marker in patients with gas-
tric cancer.
Table 1 Upregulated miRNAs associated with gastric cancer at
a cut-off value of 2-fold difference
MiRNAs Fold change
has-miR-140-5p 5.48
has-miR-409-3p 5.20
has-miR-143 5.12
has-miR-199a-5p 4.08
has-miR-423-3p 3.81
has-miR-338-3p 3.53
has-miR-33a 3.38
has-miR-652 3.17
has-miR-551b 3.15
has-miR-18a 2.64
has-miR-584 2.55
has-miR-181d 2.53
has-miR-28-5p 2.48
has-miR-627 2.46
has-miR-376a 2.45
has-miR-503 2.40
has-miR-628-3p 2.39
has-miR-1 2.37
has-miR-629 2.34
miR-625-3p 2.18
has-miR-7 2.14
has-miR-590-5p 2.07
has-miR-199a-3p 2.06
has-miR-766 2.05
has-miR-335 2.02
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Discussion
Gastroscopy remains the gold standard for detection of
gastric cancer, which usually has a high false negative
rate, due to the lack of noticeable symptoms of gas-
tric cancer. Therefore, patients usually diagnosed with
advanced cancer when underwent these examinations.
Hence, the development of gastric cancer screening
tool would effectively reduce the overall mortality. To
date, there is no reliable non-invasive blood based
classifier for the detection of gastric cancer.
Several studies reported that miRNA pattern is distinct
in different cancer types. MiR-21 is one of the miRNAs
that is known to play a role in various types of carcinomas
[15, 16], including gastric carcinoma [17]. Studies have
shown that miR-21 is known to increase in gastric cancer,
and associated with tumor cell growth and invasion
[18, 19]. However, it is not suitable to be a tissue-
specific diagnostic marker of gastric cancer, due to its
high expression in most of the cancerous tissues. This
prompted us to discover the feasibility of other miRNAs
in plasma for diagnosis.
In this study, we used a miRNA microarray platform
to screen the differentially expressed miRNAs in plasma
of gastric cancer patients, and several upregulated
miRNAs (miR-18a, miR-140-5p, 199a-3p, miR-627,
miR-629 and mir-652) were selected for validation.
We then selected the three miRNAs (miR-627, miR-
629 and miR-652) with highest ROC curve and per-
formed a large validation study on the expression levels.
In both training (n = 50) and validation sets (n = 58), these
3 miRNAs were highly expressed in gastric cancer cases
when compared with healthy controls. The algorithm we
used to optimize the gastric cancer classifier (by multipli-
cation of two highest expression levels among 3 miRNAs),
which can be used as a biomarker to discriminate gastric
cancer patients with healthy controls. The classifier was
validated again in TS and VS, and AUC were determined
to be 0.902 and 0.969 respectively with improved sensitiv-
ity and specificity when compared to individual miRNA,
implicating that this classifier is robust biomarker for gas-
tric cancer. We further validated the classifier in a RS
(mixture of gastric cancer and healthy controls samples),
and could discriminate gastric cancer patients from
healthy controls with AUC calculated to be 0.942. There is
no association between the expression levels of the classi-
fier (or individual miRNAs) and TNM stage in plasma of
gastric cancer patients. It is widely accepted that miRNA
is being released into the circulation from the primary
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Fig. 2 Validation of plasma (a) miR-18a, (b) miR-140-5p, (c) 199a-3p, (d) miR-627, (e) miR-629 and (f) miR-652 levels in training set (TS). Expression
levels were normalized to U6. Box plots of six miRNAs in plasma of gastric cancer patients (n = 50) and healthy controls (n = 50) The boxes mark
the interval between the 25th and 75th percentiles, and the lines inside the box denote the medians. The whiskers represent the interval between
the 10th and 90th percentiles. Statistically significant differences were analyzed using Mann–Whitney test. Receiver-operating characteristic (ROC)
curve analysis of miRNA for discriminating gastric cancer patients from healthy controls
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gastric cancer site, therefore it is expected to detect a
similar trend of elevation of miRNA expression in
gastric cancer tissues. A consistent higher expression
levels of miR-627, miR-629 and miR-652 were de-
tected in tumor tissues than adjacent non-tumor
counterparts (n = 36) (Fig. 3b), which echoed with the
findings in plasma of gastric cancer patients.
To the best of our knowledge, this is the first study
reported that expression of plasma miR-627 is more
than 10-fold higher in gastric cancer patients than in
healthy controls. It is worthwhile to investigate the
specificity of this miRNA by examining its expression in
other cancerous tissues. High level of miR-629* was
detected in the plasma of xenograft mice which is
originated from human prostate cancer xenograft [14].
This study provide evidence that tumor-derived miRNA
could be detected in the circulation. Several studies re-
ported that mir-652 is associated with tumor progression
of osteosarcoma [20] and hepatocellular carcinoma [21].
Another group reported that deregulation of miR-652
was identified as a biomarker for schizophrenia [22].
However, in primary squamous cell lung carcinoma
tissues, the levels of miR-652 were downregulated as
compared with normal counterparts [23]. These studies
revealed that the function of miRNA is different in
various carcinomas and yet further study mechanistic
on the oncogenic pathways may help to understand
the progression of the disease.
Conclusion
In conclusion, our data demonstrated that circulating
miRNAs could be a sensitive biomarker for diagnosis of
gastric cancer. This study revealed a new algorithm to
discriminate gastric cancer cases and non-gastric cancer
cases, the classifier (by combining 3 miRNAs) illustrated
a promising discrimination of gastric cancer cases in
different validation sets, which is far more sensitive than
conventional tumor marker (eg CEA and CA 19.9).
Further studies are warranted to examine the expression
levels of selected miRNAs after surgery to verify the
usefulness of the classifier to predict recurrence or
therapeutic strategy during follow-up. This study may
open up new opportunity to develop an economical
non-invasive diagnostic tool for early detection of gastric
cancer to reduce mortality.
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Fig. 3 Selection and validation of (a) miR-18a, (b) miR-140-5p, (c) 199a-3p, (d) miR-627, (e) miR-629 and (f) miR-652 in an independent validation
set (VS). Box plots and ROC curve analysis of miRNAs in the plasma of gastric cancer patients (n = 58) and healthy controls (n = 46). The boxes
mark the interval between the 25th and 75th percentiles, and the lines inside the box denote the medians. The whiskers represent the interval
between the 10th and 90th percentiles. Statistically significant differences were analyzed using Mann–Whitney test. Receiver-operating characteristic
(ROC) curve analysis of miRNA for discriminating gastric cancer patients from healthy controls
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Methods
Clinical samples
Pre-resection plasma and respective paired primary
tumor/adjacent non-tumor tissue samples were obtained
at Queen Mary Hospital between 2006 to 2010, while
healthy volunteers were recruited at the Hong Kong
Sanatorium and Hospital from 2009–2010. To discover
and validate a specific biomarker for gastric cancer, this
study consists of 3 independent sets of cases and con-
trols. The training set (TS) contained 50 gastric cancer
cases from 2006–2007, validation set (VS) contain 58
gastric cancer cases from 2008–2010 and random set
contain 15 gastric cancer cases from 2008–2010, each
independent set includes stage I to IV patients.
Plasma and tissue samples are stored at the frozen tissue
bank of the Department. The collection and storage of
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Table 2 ROC curve analyses of the potential classifiers
TS VS
Classifier Sensitivity Specificity AUC 95 % CI Sensitivity Specificity AUC 95 % CI
Classifier A (miR-627 & miR-629) 0.804 0.773 0.878 0.814–0.942 0.9 0.894 0.948 0.905–0.990
Classifier B (miR-627 & miR-652) 0.821 0.757 0.842 0.763–0.922 0.88 0.935 0.965 0.931–0.991
Classifier C (miR-629 & miR-652) 0.800 0.821 0.884 0.817–0.952 0.960 0.837 0.963 0.932–0.995
Classifier D (miR-627, miR-629 & miR-652) 0.855 0.757 0.902 0.842–0.962 0.92 0.935 0.969 0.938–1.001
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such tissue samples have been approved by the Institu-
tional Review Board. Informed consent has been obtained
from each patient. Characteristics of patients such as
gender, age, co-morbidity, presenting symptoms and signs,
operative findings and staging will be prospectively
collected into our standard electronic database. Clinical
characteristics of gastric cancer patients were summarized
in Table 3. These gastric plasma/tissues will be subjected
to miRNA profiling and correlated with the clinicopatho-
logical factors in gastric cancer patients.
MiRNA extraction
Total RNA containing small RNA was extracted from
500 μl of plasma using Trizol LS reagent (Invitrogen,
Carlsbad, California, USA) and miRNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. After phase separation by chloroform
addition and centrifugation, 1.5 volumes of 100 % ethanol
was added to the aqueous phase and the mixture was
loaded into miRNeasy column (Qiagen). DNase treatment
(Qiagen) was carried out to remove any contaminating
DNA. The final elution volume was 30 μl. The concentra-
tions of all RNA samples were quantified by NanoDrop
1000 (Nanodrop, Wilmington, Delaware, USA).
MiRNA microarray
In the screening phase, we profiled 10 age- and sex-
matched individuals (5 gastric cancer patients vs 5
normal controls) using a miRCURY LNA Array (Exiqon)
which contained 730 human miRNAs. This system is a
real-time PCR-based array containing a panel of 384 well-
established mature miRNA assays. The kit contains all
reagents and primers, reverse transcription and qPCR. In
brief, a poly-A tail is added to the mature miRNA template
and then synthesized to cDNA by a poly-T primer with a
3′ degenerate anchor and 5′ universal tag. The cDNA is
amplified by miRNA-specific and LNA™ -enhanced
forward and reverse primers. SYBR Green PCR will be
performed in LC480 Real-time PCR system (Roche).
MiRNA validation by real-time quantitative RT-PCR
Plasma/tissues RNA containing miRNA is reverse tran-
scribed to cDNA using miScript Reverse Transcription
kit (Qiagen) according to the manufacturer’s instruc-
tions. qPCR is performed using SYBR real-time PCR
using miScript SYBR Green PCR kit (Qiagen) with the
manufacturer provided miScript Universal primer and
the miRNA-specific forward primers in ABI 7900 Real-
time PCR system (Applied Biosystems). The miRNA-
specific primer sequences are designed by us based on
the miRNA sequences obtained from the miRBase
database (release 19). Each sample is run in duplicates
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The whiskers represent the interval between the 10th and 90th
percentiles. Statistically significant differences were analyzed using
Mann–Whitney test
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Fig. 6 Correlation between gastric cancer classifier and tumor stage
in plasma of gastric cancer patients (n = 123)
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and the expression levels of miRNAs are normalized to
an endogenous control RNU6B (U6). Fold change in
expression of each gene is calculated by a compara-
tive threshold cycle (Ct) method using the formula:
2-[ΔCt(tumor)- ΔCt(control)].
Statistical analysis
The significance of plasma miRNA levels was deter-
mined by the Mann–Whitney test, Wilcoxon test, t-test or
Kruskal–Wallis test where appropriate. The Spearman
rank order correlation test was used to examine
correlation relationships between the levels of the
miRNA markers. Multivariate logistic regression
model will be established and leave-one-out cross val-
idation will be performed to find the logistic model.
Receiver operating characteristic (ROC) curves were
established for discriminating patients with or without
gastric cancer. All P-values are two-sided and a value
less than 0.05 were considered statistically significant.
All statistical calculations were performed by the
SPSS software (version 17.0).
Additional file
Additional file 1: Table S1. Downregulated miRNAs associated with
gastric cancer at a cut-off value of 2-fold difference. (DOCX 16 kb)
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Table 3 Clinical characteristics of gastric cancer patient
Training set
(n = 50)
Validation set
(n = 58)
Random set
(n = 15)
P value Total
(n = 123)
Age [years; mean (SD)] 62.8 (18.3) 67.2 (16.4) 67.1 (13.4) 0.366 64.40 (16.88)
Sex 0.499
Men 31 33 11 75/123 (61 %)
Women 19 25 4 48/123 (39 %)
Depth of invasion (T) 0.932
T1 7 4 2 13/123 (11 %)
T2 12 13 3 28/123 (23 %)
T3 18 25 6 49/123 (40 %)
T4 13 16 4 33/123 (27 %)
Lymph-node metastasis 0.361
(N) 13 10 4 27/123 (22 %)
N0 10 8 2 20/123 (16 %)
N1 26 40 8 74/123 (60 %)
N2 1 0 1 2/123 (2 %)
N3
Distant metastasis 0.554
No 37 46 13 96/123 (78 %)
Yes 13 12 2 27/123 (22 %)
Stage 0.088
I 8 8 4 20/123 (16 %)
II 11 2 2 15/123 (12 %)
III 15 26 5 46/123 (38 %)
IV 16 22 4 42/123 (34 %)
Shin et al. Molecular Cancer  (2015) 14:202 Page 8 of 9
Received: 6 July 2015 Accepted: 18 November 2015
References
1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent
patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666–73.
2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report
on poor survival of U.S. gastric carcinoma patients treated with gastrectomy:
Fifth Edition American Joint Committee on Cancer staging, proximal disease,
and the “different disease” hypothesis. Cancer. 2000;88:921–32.
3. Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, He H, et al. Serum macrophage
migration-inhibitory factor as a diagnostic and prognostic biomarker for
gastric cancer. Cancer. 2009;115:5441–9.
4. Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, et al. Soluble E-
cadherin is a valid prognostic marker in gastric carcinoma. Gut. 2001;48:808–11.
5. Chan AO, Chu KM, Lam SK, Cheung KL, Law S, Kwok KF, et al. Early
prediction of tumor recurrence after curative resection of gastric carcinoma
by measuring soluble E-cadherin. Cancer. 2005;104:740–6.
6. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med.
2005;11:712–4.
7. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al.
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 2005;37:766–70.
8. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E.
Phylogenetic shadowing and computational identification of human
microRNA genes. Cell. 2005;120:21–4.
9. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, et al.
Prognostic Significance of miR-215 in Colon Cancer. Clin Colorectal Cancer.
2011;10:340–7.
10. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21
expression in breast cancer associated with poor disease-free survival in early
stage disease and high TGF-beta1. Breast Cancer Res Treat. 2009;117:131–40.
11. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of
miR-122 expression in liver cancer correlates with suppression of the
hepatic phenotype and gain of metastatic properties. Oncogene.
2009;28:3526–36.
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression
of microRNAs in plasma of patients with colorectal cancer: a potential
marker for colorectal cancer screening. Gut. 2009;58:1375–81.
13. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer
and other diseases. Cell Res. 2008;18:997–1006.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan
EL, et al. Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
15. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A
microRNA expression signature of human solid tumors defines cancer gene
targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.
16. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer. 2006;6:259–69.
17. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al.
Circulating microRNAs in plasma of patients with gastric cancers. Br J
Cancer. 2010;102:1174–9.
18. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, et al. miR-21 plays a
pivotal role in gastric cancer pathogenesis and progression. Lab Invest.
2008;88:1358–66.
19. Shin VY, Jin H, Ng EK, Cheng AS, Chong WW, Wong CY, et al. NF-kappaB
targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E
receptors. Carcinogenesis. 2011;32:240–5.
20. Lulla RR, Costa FF, Bischof JM, Chou PM, de F Bonaldo M, Vanin EF, et al.
Identification of Differentially Expressed MicroRNAs in Osteosarcoma.
Sarcoma. 2011;2011:732690.
21. Sukata T, Sumida K, Kushida M, Ogata K, Miyata K, Yabushita S, et al.
Circulating microRNAs, possible indicators of progress of rat
hepatocarcinogenesis from early stages. Toxicol Lett. 2011;200:46–52.
22. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC, et al. MicroRNA
Expression Aberration as Potential Peripheral Blood Biomarkers for
Schizophrenia. PLoS One. 2011;6:e21635.
23. Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary
squamous cell lung carcinoma is associated with poor patient prognosis.
J Cancer Res Clin Oncol. 2011;137:557–66.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shin et al. Molecular Cancer  (2015) 14:202 Page 9 of 9
